Abstract
Alzheimer’s disease (AD) is a chronic age-related neurodegenerative disease characterized by degeneration of the central cholinergic neurons, inflammation and oxidative stress in the basal forebrain, prefrontal cortex and hippocampus. Hesperidin (Hesp) is one of the flavonoids havinganti-inflammatory and anti-oxidative properties in some neurodegerative brain lesions. To investigate the possible neuroprotective role of Hespin an AD-like rat model induced experimentally by Scopolamine (Scop). Forty adult male Sprague Dawley rats were randomly allocated into four groups. Group I—(Control), group II—(Hesp) (supplemented orally with 100 mg/kg Hesp for 28 days), group III—(AD) (injected i.p with 1 mg/kg Scop for 9 days) and group IV—(Hesp/AD). At the end of the experiment, behavioral (Y-maze test) and biochemical analysis were carried out along with histological, immunohistochemical and morphometric studies of the hippocampus and prefrontal cortex. AD rats displayed memory impairment in the behavioural paradigm with a concomitant increase of serum TNF-α and IL-1β, while IL-10 decreased significantly. Also, there was a rise of amyloid beta-42 (Aβ-42), acetylcholinesterase (AChE) activity and malondialdehyde (MDA) together with a decrease of reduced glutathione (GSH) in hippocampal and prefrontal homogenate. In addition, sections of the hippocampus and prefrontal cortex revealed obvious histopathological changes, overexpression of p-Tau protein and glial fibrillary acidic protein (GFAP) with a decrease in the expression of synaptophysin (SYN). Contradictorily, pre-treatment with Hesp offset the spatial memory deficits, redox imbalance, Aβ-42 and AChE over activity as well as preserved the histological architecture and attenuated the raised p-Tau protein and GFAP while upregulated SYN immuoreactivity of AD rats. Collectively, our results highlight the potential mitigating role of Hesp in AD-like state in rats and this may presumably raise the possibility of its future implementation as a prophylactic remedy against AD in humans.
Graphic abstract
Similar content being viewed by others
References
Adams SV, Winterer J, Müller W (2004) Muscarinic signaling is required for spike-pairing induction of long-term potentiation at rat Schaffer collateral-CA1 synapses. Hippocampus 14(4):413–416. https://doi.org/10.1002/hipo.10197
Anand KS, Dhikav V (2012) Hippocampus in health and disease: an overview. Ann Indian Acad Neurol 15(4):239
Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology 76:27–50. https://doi.org/10.1016/j.neuropharm.2013.07.004
Angelo M, Plattner F, Giese KP (2006) Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J Neurochem 99(2):353–370
Association A (2018) 2018 Alzheimer’s disease facts and figures. Alzheimers Dement 14(3):367–429
Association A (2019) 2019 Alzheimer’s disease facts and figures. Alzheimers Dement 15(3):321–387
Bassani TB, Bonato JM, Machado MM, Cóppola-Segovia V, Moura EL, Zanata SM, Vital MA (2018) Decrease in adult neurogenesis and neuroinflammation are involved in spatial memory impairment in the streptozotocin-induced model of sporadic Alzheimer’s disease in rats. Mol Neurobiol 55(5):4280–4296. https://doi.org/10.1007/s12035-017-0645-9
Bhuvanendran S, Kumari Y, Othman I, Shaikh MF (2018) Amelioration of cognitive deficit by embelin in a scopolamine-induced Alzheimer’s disease-like condition in a rat model. Front Pharmacol 9:665. https://doi.org/10.3389/fphar.2018.00665
Brivanlou IH, Dantzker JL, Stevens CF, Callaway EM (2004) Topographic specificity of functional connections from hippocampal CA3 to CA1. Proc Natl Acad Sci 101(8):2560–2565
Cheong MY, Yun SH, Mook-Jung I, Joo I, Huh K, Jung MW (2001a) Cholinergic modulation of synaptic physiology in deep layer entorhinal cortex of the rat. J Neurosci Res 66(1):117–121
Cheong MY, Yun SH, Mook-Jung I, Joo I, Huh K, Jung MW (2001b) Cholinergic modulation of synaptic physiology in deep layer entorhinal cortex of the rat. J Neurosci Res 66(1):117–121. https://doi.org/10.1002/jnr.1203
Christopher MA, Myrick DA, Barwick BG, Engstrom AK, Porter-Stransky KA, Boss JM, Katz DJ (2017) LSD1 protects against hippocampal and cortical neurodegeneration. Nat Commun 8(1):1–13. https://doi.org/10.1038/s41467-017-00922-9
Citron M (2010) Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 9(5):387–398
de Andrade Teles RB, Diniz TC, Costa Pinto TC, de Oliveira Júnior RG, Gama e Silva M, de Lavor EM, da Silva Almeida JRG (2018) Flavonoids as therapeutic agents in Alzheimer’s and Parkinson’s diseases: a systematic review of preclinical evidences. Oxid Med Cell Longev. https://doi.org/10.1155/2018/7043213
Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82(1):70–77
Fakhoury M (2018) Microglia and astrocytes in Alzheimer’s disease: implications for therapy. Curr Neuropharmacol 16(5):508–518
Garman RH (2011) Histology of the central nervous system. Toxicol Pathol 39(1):22–35. https://doi.org/10.1177/0192623310389621
Giese KP (2009) GSK-3: a key player in neurodegeneration and memory. IUBMB Life 61(5):516–521
Gupta R, Gupta LK, Mediratta PK, Bhattacharya SK (2012) Effect of resveratrol on scopolamine-induced cognitive impairment in mice. Pharmacol Rep 64(2):438–444. https://doi.org/10.1016/S1734-1140(12)70785-5
Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian ZS (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141(7):1917–1933. https://doi.org/10.1093/brain/awy132
Ikemura M, Sasaki Y, Giddings JC, Yamamoto J (2012) Preventive effects of hesperidin, glucosyl hesperidin and naringin on hypertension and cerebral thrombosis in stroke-prone spontaneously hypertensive rats. Phytother Res 26(9):1272–1277
Imbimbo BP, Lombard J, Pomara N (2005) Pathophysiology of Alzheimer’s disease. Neuroimaging Clin 15(4):727–753
Iqbal K, Alonso ADC, Chen S, Chohan MO, El-Akkad E, Gong CX, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochimica Et Biophysica Acta (BBA) Mol Basis Dis 1739(2–3):198–210. https://doi.org/10.1016/j.bbadis.2004.09.008
Javed H, Vaibhav K, Ahmed ME, Khan A, Tabassum R, Islam F, Islam F (2015) Effect of hesperidin on neurobehavioral, neuroinflammation, oxidative stress and lipid alteration in intracerebroventricular streptozotocin induced cognitive impairment in mice. J Neurol Sci 348(1–2):51–59
Jawaid T, Shakya AK, Siddiqui HH, Kamal M (2014) Evaluation of Cucurbita maxima extract against scopolamine-induced amnesia in rats: implication of tumour necrosis factor alpha. Zeitschriftfür Naturforschung c 69(9–10):407–417
Jeon HJ, Seo MJ, Choi HS, Lee OH, Lee BY (2014) Gelidium elegans, an edible red seaweed, and hesperidin inhibit lipid accumulation and production of reactive oxygen species and reactive nitrogen species in 3T3-L1 and RAW264.7 cells. Phytother Res 28(11):1701–1709. https://doi.org/10.1002/ptr.518
Jin J, Maren S (2015) Prefrontal-hippocampal interactions in memory and emotion. Front Syst Neurosci 9:170. https://doi.org/10.3389/fnsys.2015.00170
Justin Thenmozhi A, William Raja TR, Manivasagam T, Janakiraman U, Essa MM (2017) Hesperidin ameliorates cognitive dysfunction, oxidative stress and apoptosis against aluminium chloride induced rat model of Alzheimer’s disease. Nutr Neurosci 20(6):360–368
Kakadiya J, Mulani H, Shah N (2010) Protective effect of hesperidin on cardiovascular complication in experimentally induced myocardial infarction in diabetes in rats. J Basic Clin Pharm 1(2):85
Kälin AM, Park M, Chakravarty MM, Lerch JP, Michels L, Schroeder C, Leh SE (2017) Subcortical shape changes, hippocampal atrophy and cortical thinning in future Alzheimer’s disease patients. Front Aging Neurosci 9:38. https://doi.org/10.3389/fnagi.2017.00038
Kashyap G, Bapat D, Das D, Gowaikar R, Amritkar RE, Rangarajan G, Ambika G (2019) Synapse loss and progress of Alzheimer’s disease-A network model. Sci Rep 9(1):1–9
Khan S, Shad KF (2020) Neuroprotective effects of curcumin and vitamin D3 on scopolamine-induced learning-impaired rat model of Alzheimer’s disease. In Neurological and Mental Disorders. IntechOpen
Kim DO, Jeong SW, Lee CY (2003) Antioxidant capacity of phenolic phytochemicals from various cultivars of plums. Food Chem 81(3):321–326. https://doi.org/10.1016/S0308-8146(02)00423-5
Kim SU, de Vellis J (2005) Microglia in health and disease. J Neurosci Res 81(3):302–313. https://doi.org/10.1002/jnr.20562
Kumar P, Kumar A (2010) Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington’s like symptoms in rats: possible role of nitric oxide. Behav Brain Res 206(1):38–46. https://doi.org/10.1016/j.bbr.2009.08.028
Kwon SH, Kim HC, Lee SY, Jang CG (2009) Loganin improves learning and memory impairments induced by scopolamine in mice. Eur J Pharmacol 619(1–3):44–49. https://doi.org/10.1016/j.ejphar.2009.06.062
Lakshmi BVS, Sudhakar M, Prakash KS (2015) Protective effect of selenium against aluminum chloride-induced Alzheimer’s disease: behavioral and biochemical alterations in rats. Biol Trace Elem Res 165(1):67–74
Lalonde R (2002) The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 26(1):91–104. https://doi.org/10.1016/S0149-7634(01)00041-0
Lee JS, Kim HG, Lee HW, Han JM, Lee SK, Kim DW, Son CG (2015) Hippocampal memory enhancing activity of pine needle extract against scopolamine-induced amnesia in a mouse model. Sci Rep 5(1):1–10
Li K, Li J, Zheng J, Qin S (2019) Reactive astrocytes in neurodegenerative diseases. Aging Dis 10(3):664
Liddelow SA, Barres BA (2017) Reactive astrocytes: production, function, and therapeutic potential. Immunity 46(6):957–967. https://doi.org/10.1016/j.immuni.2017.06.006
Lim JW, Lee J, Pae AN (2020) Mitochondrial dysfunction and Alzheimer’s disease: prospects for therapeutic intervention. BMB Rep 53(1):47
Liu YH, Lee CJ, Chen LC, Lee TL, Hsieh YY, Han CH, Hou WC (2020) Acetylcholinesterase inhibitory activity and neuroprotection in vitro, molecular docking, and improved learning and memory functions of demethyl curcumin in scopolamine-induced amnesia ICR mice. Food Funct 11(3):2328–2338
Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G (2016) Therapies for prevention and treatment of Alzheimer’s disease. Biomed Res Int. https://doi.org/10.1155/2016/2589276
Morrison AS, Lyketsos C (2005) The pathophysiology of Alzheimer’s disease and directions in treatment. Adv Stud Nurs 3(8):256–270
Nijveldt RJ, Van Nood ELS, Van Hoorn DE, Boelens PG, Van Norren K, Van Leeuwen PA (2001) Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 74(4):418–425. https://doi.org/10.1093/ajcn/74.4.418
Odukoya O, Sofidiya M, Ilori O, Gbededo M, Ajadotuigwe J, Olaleye O, Brinkhaus B (1994) Malondialdehyde determination as index of lipid peroxidation. Int J Biol Chem 3:281–285
Pagnier GJ, Kastanenka KV, Sohn M, Choi S, Choi SH, Soh H, Bacskai BJ (2018) Novel botanical drug DA-9803 prevents deficits in Alzheimer’s mouse models. Alzheimer’s Res Ther 10(1):1–13
Pattanashetti LA, Taranalli AD, Parvatrao V, Malabade RH, Kumar D (2017) Evaluation of neuroprotective effect of quercetin with donepezil in scopolamine-induced amnesia in rats. Indian J Pharmacol 49(1):60
Paul CM, Magda G, Abel S (2009) Spatial memory: theoretical basis and comparative review on experimental methods in rodents. Behav Brain Res 203(2):151–164. https://doi.org/10.1016/j.bbr.2009.05.022
Perl DP (2010) Neuropathology of Alzheimer’s disease. Mt Sinai J Med 77(1):32–42
Popović M, Caballero-Bleda M, Benavente-García O, Castillo J (2014) The flavonoid apigenin delays forgetting of passive avoidance conditioning in rats. J Psychopharmacol 28(5):498–501. https://doi.org/10.1177/0269881113512040
Poulakis K, Pereira JB, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, Westman E (2018) Heterogeneous patterns of brain atrophy in Alzheimer’s disease. Neurobiol Aging 65:98–108
Rahnama S, Rabiei Z, Alibabaei Z, Mokhtari S, Rafieian-Kopaei M, Deris F (2015) Anti-amnesic activity of Citrus aurantium flowers extract against scopolamine-induced memory impairments in rats. Neurol Sci 36(4):553–560
Raza SS, Khan MM, Ahmad A, Ashafaq M, Khuwaja G, Tabassum R, Islam F (2011) Hesperidin ameliorates functional and histological outcome and reduces neuroinflammation in experimental stroke. Brain Res 1420:93–105. https://doi.org/10.1016/j.brainres.2011.08.047
Rybakowski JK (2018) Lithium in Alzheimer’s disease: experimental, epidemiological and clinical findings. In: Dorszewska J, Kozubski W (eds) Alzheimer’s disease. The 21st century challenge. IntechOpen, London, pp 79–89
Salem HRA, El-Raouf AA, Saleh EM, Shalaby KA (2012) Influence of hesperidin combined with Sinemet on genetical and biochemical abnormalities in rats suffering from Parkinson’s disease. Life Sci J 9(4):930–945
Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205
Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, Wharton SB (2010) Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging 31(4):578–590. https://doi.org/10.1016/j.neurobiolaging.2008.05.015
Suvarna KS, Layton C, Bancroft JD (2018) Bancroft’s theory and practice of histological techniques. E-Book, Elsevier Health Sciences. Churchill Livingstone
Tabatabaei-Jafari H, Shaw ME, Walsh E, Cherbuin N et al (2019) Regional brain atrophy predicts time to conversion to Alzheimer’s disease, dependent on baseline volume. Neurobiol Aging 83:86–94
Talesa VN (2001) Acetylcholinesterase in Alzheimer’s disease. Mech Ageing Dev 122(16):1961–1969. https://doi.org/10.1016/S0047-6374(01)00309-8
Tamilselvam K, Braidy N, Manivasagam T, Essa MM, Prasad NR, Karthikeyan S, Guillemin GJ (2013) Neuroprotective effects of hesperidin, a plant flavanone, on rotenone-induced oxidative stress and apoptosis in a cellular model for Parkinson’s disease. Oxid Med Cell Longev. https://doi.org/10.1155/2013/102741
Uddin MS, Kabir MT, Al Mamun A, Barreto GE, Rashid M, Perveen A, Ashraf GM (2020) Pharmacological approaches to mitigate neuroinflammation in Alzheimer’s disease. Int Immunopharmacol 84:106479. https://doi.org/10.1016/j.intimp.2020.106479
Van Cauwenberghe C, Van Broeckhoven C, Sleegers K (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 18(5):421–430
Wall PM, Messier C (2002) Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory. Psychopharmacology 160(3):233–244
Wan T, Wang Z, Luo Y, Zhang Y, He W, Mei Y, Huang Y (2019) FA-97, a new synthetic caffeic acid phenethyl ester derivative, protects against oxidative stress-mediated neuronal cell apoptosis and scopolamine-induced cognitive impairment by activating Nrf2/HO-1 signaling. Oxid Med Cell Longev. https://doi.org/10.1155/2019/8239642
Wu XL, Piña-Crespo J, Zhang YW, Chen XC, Xu HX (2017) Tau-mediated neurodegeneration and potential implications in diagnosis and treatment of Alzheimer’s disease. Chin Med J 130(24):2978
Zhang J, Zhen YF, Song LG, Kong WN, Shao TM, Li X, Chai XQ (2013) Salidroside attenuates beta amyloid-induced cognitive deficits via modulating oxidative stress and inflammatory mediators in rat hippocampus. Behav Brain Res 244:70–81. https://doi.org/10.1016/j.bbr.2013.01.037
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mandour, D.A., Bendary, M.A. & Alsemeh, A.E. Histological and imunohistochemical alterations of hippocampus and prefrontal cortex in a rat model of Alzheimer like-disease with a preferential role of the flavonoid “hesperidin”. J Mol Histol 52, 1043–1065 (2021). https://doi.org/10.1007/s10735-021-09998-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10735-021-09998-6